Global 3D Printed Drugs Market (2018-2025)-GMI Research Global 3D Printed Drugs Market (2018-2025)-GMI Res | Page 2

seizers in 2015 and in the same year, it was introduced by Aprecia
Pharmaceuticals in the US. The 3D printed drugs can be manufactured only if the
FDA passes a priority review voucher for the proposed drugs.
Download Sample Brochure : https://www.gmiresearch.com/sample-research-
report.php?rid=142
The major factors that are propelling the growth of the 3D printed drugs are
technological innovations in 3D printing procedures, user-friendly and easy
availability. In addition, it is expected that in the coming years, the ability to
print drugs on-demand would reduce the 3D printed drug cost, lower the risk of
counterfeiting and would be able to deliver the personalize drug to individual
patients i.e. catering the needs of the patient. Further, one of the key factors
resulting in the high demand for 3D printed drugs is their instant solubility. 3D
printed drugs are easy to swallow, thus, are being used for epilepsy patients,
aged population and infants.
Various players and universities operating in the 3D printed drugs market include
3D Printer Drug Machine, Aprecia Pharmaceuticals, FabRx Ltd, GlaxoSmithKline
Plc., Hewlett Packard Caribe, BV, National University of Singapore, The
University of Nottingham, UCL School of Pharmacy, University College of London,
University of Glasgow and others
The global 3D printed drugs market has been segmented based on technology
type and key geographies. Based on technology type, the market comprises of
fused deposition modelling, inkjet printing, and others. This research report on
3D printed drugs market provides in-depth analysis of the global 3D printed drugs
market based on technique type and major geographies for the forecast period
from 2018 to 2025. The report highlights the major market drivers propelling the
growth as well as challenges faced by market participants. The research report